23,323 Shares in Alpha Tau Medical Ltd. (NASDAQ:DRTS) Purchased by Caprock Group LLC

Caprock Group LLC bought a new stake in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 23,323 shares of the company’s stock, valued at approximately $59,000.

A number of other institutional investors have also modified their holdings of DRTS. Private Advisor Group LLC purchased a new stake in Alpha Tau Medical during the fourth quarter worth $176,000. USAdvisors Wealth Management LLC bought a new stake in shares of Alpha Tau Medical in the 1st quarter valued at about $30,000. Aptus Capital Advisors LLC grew its position in shares of Alpha Tau Medical by 83.7% in the 2nd quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company’s stock worth $56,000 after buying an additional 10,000 shares during the last quarter. Financial Guidance Group Inc. raised its stake in shares of Alpha Tau Medical by 83.7% during the 2nd quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company’s stock worth $56,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Levin Capital Strategies L.P. lifted its position in Alpha Tau Medical by 2.6% during the first quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company’s stock valued at $999,000 after acquiring an additional 8,641 shares during the last quarter. 2.65% of the stock is owned by hedge funds and other institutional investors.

Alpha Tau Medical Trading Down 2.5 %

Shares of Alpha Tau Medical stock opened at $2.34 on Friday. Alpha Tau Medical Ltd. has a 12-month low of $1.75 and a 12-month high of $3.90. The firm’s 50 day simple moving average is $2.19 and its two-hundred day simple moving average is $2.47. The company has a current ratio of 11.66, a quick ratio of 11.60 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $163.03 million, a price-to-earnings ratio of -5.71 and a beta of 0.77.

Alpha Tau Medical (NASDAQ:DRTS) last released its earnings results on Wednesday, August 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. Analysts predict that Alpha Tau Medical Ltd. will post -0.48 EPS for the current year.

Wall Street Analyst Weigh In

DRTS has been the topic of a number of recent analyst reports. Piper Sandler reaffirmed an “overweight” rating and set a $7.00 price target on shares of Alpha Tau Medical in a research report on Thursday, August 15th. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Alpha Tau Medical in a research note on Tuesday, August 20th.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.